Lifeboat Foundation

The Expedition 66 crew continued preparing today for the first of two spacewalks set to begin next week to continue upgrading the International Space Station’s power system. Vein scans were also on Thursday’s schedule helping scientists understand how living in space affects the human body.

NASA Flight Engineers Kayla Barron and Raja Chari are set to switch their U.S. spacesuits to battery power at 8:05 a.m. EDT on Tuesday and spend six-and-a-half hours installing a modification kit on the space station’s Starboard-4 truss structure. The new hardware will enable the upcoming installation of a third roll-out solar array increasing the station’s power output and augmenting the existing solar arrays.

The duo was joined by fellow station astronauts Tom Marshburn of NASA and Matthias Maurer of ESA (European Space Agency) for a spacewalk procedures review and conference with specialists on the ground. Marshburn and Maurer will assist the spacewalkers in and out of their spacesuits, operate the Canadarm2 robotic arm, and monitor their external activities. Mission managers will talk about the spacewalk, as well as a second one planned for March 23, live on the NASA TV app and the website on Monday at 2 p.m. NASA TV begins its live spacewalk broadcast on Tuesday at 6:30 a.m.

An AI-trained surgical robot that can make a few stitches on its own is a small step toward systems that can aid surgeons with such repetitive tasks.

The robot was able to sew six stitches all on its own—and has lessons for robotics as a whole.

A team of Rutgers undergraduates has shown that an experimental drug known as Yoda1 may help drain cranial waste plus neurotoxins that cause Alzheimer’s disease and other forms of dementia.

Rutgers study led by undergrads and gap-year students breaks ground in the field of neuroscience and suggests experimental medication could treat dementia.

“This trial has changed the lives of people with mesothelioma, allowing us to live longer,” said one of the patients who benefited from the drug. The 80-year-old, who wished to remain anonymous, won compensation from his former employer after being exposed to asbestos in a factory in the 1970s.

He was given four months to live, but thanks to the trial is still alive five years later. “I have five grandchildren and two great-grandchildren now – I wouldn’t want to miss all that,” he said.

The breakthrough is significant, experts say, because mesothelioma has one of the lowest survival rates of any cancer. The new drug, ADI-PEG20 (pegargiminase), is the first of its kind to be successfully combined with chemotherapy in 20 years.

Groundbreaking research led by a global group of over 100 researchers will enable a more in-depth exploration of human genetic variation as fully sequencing the Y chromosome, a feat that has challenged scientists for years, has been accomplished for the first time. In this interview, we speak to Dylan Taylor about this impactful research and how it may shape our understanding of human genetics.

Please could you introduce yourself and your current research activities?

I am Dylan Taylor, a Ph.D. candidate and NIH F31 fellow in the Department of Biology at Johns Hopkins University. My work with the T2T consortium focuses on exploring how a complete reference genome can improve our ability to study human genetic variation and how it impacts human traits and health.

Polyploidization-rediploidization process plays an important role in plant adaptive evolution. Here, the authors assemble the genomes of mangrove species Sonneratia alba and its inland relative Lagerstroemia speciosa, and reveal genomic evidence for rediploidization and adaptive evolution after the whole-genome triplication.

I have written a lot about vaccines that treat cancer. Now we have another new mRNA vaccine to treat pancreatic cancer that has shown promising results in phase 1 clinical trials and is now entering a larger phase 2 clinical trial. This is exciting news for a deadly cancer that attacks tens of thousands of people each year.

The mRNA vaccine technology is going to be one of the leading technologies for cancer treatments going forward. If it can make a meaningful dent in the course of pancreatic cancer, it may well become one of the primary tools for oncologists in treating this pernicious disease.

As I usually do, let’s review this vaccine and the clinical trial results.

Miotto et al. show that in mice, liver-derived extracellular vesicles act on skeletal muscle and the pancreas and increase glucose effectiveness and insulin secretion, thereby modulating glycaemic control.

Discussions are emerging about conducting clinical trials on humans with nanorobots for medical applications. Currently, in the United States, four burgeoning companies are striving towards this aim, working to advance their nanomachines into Phase 1 studies, subsequent to laboratory research and preclinical trials on animals.

The article “Delivering drugs with microrobots”, published in Science on December 7, 2023, has recaptured the international scientific community’s attention on the practical, effective use of nanorobots in Clinical Practice and Medicine.

Its author, Bradley Nelson, a Robotics and Intelligent Systems professor at ETH Zurich, poses a straightforward question: where are these diminutive biocompatible machines, designed to be injected into the human body for more efficient exploration, internal repair, and precise, targeted drug delivery? Researchers have discussed them for years – he notes – yet we still do not see them progressing from laboratories to the forefront of clinical trials. How close are we to this milestone?